Date: December 03, 2018 to December 05, 2018
Where: DoubleTree Suites by Hilton Hotel Boston - Cambridge, 400 Soldiers Field Road Boston, Allston, Massachusetts, United States, 02134
Ticket Price: N/A
With our increased understanding of RNA structure and function, and RNA-small molecule binding behaviour a plethora of previously undruggable targets are opening up. As such, I wanted to introduce to you to the 1st RNA-Targeted Drug Discovery Summit 2018 (Boston, MA - December 3-6, 2018) - a niche scientific and networking forum, carefully curated from those at large pharma, biotech and academia who are pioneering the next generation of small molecule drug discovery. The 1st RNA-Targeted Drug Discovery Summit will bring together a unique community of experts, devoted to optimizing the process of discovering and designing small molecules that bind specifically to quality RNA targets and translating these into clinically safe and effective therapies. Sounds interesting? Get your free event brochure copy to find out more: http://bit.ly/2C7derg Meet with experts and come away with: ? Deep understanding of how to translate the structure, dynamics and function of RNA into lead small molecules with insights from Matthew Disney, Founder, Expansion Therapeutics & Professor, Scripps Research Institute. Explore experimental approaches that support target engagement in cells to support compound mode of action. ? Explore the discovery, structure and cellular activity of small molecule inhibitors of cellular and viral RNAs through the insights delivered by Gabriele Varani, Professor of Chemistry, University of Washington. ? Understand principles for targeting RNA with small molecules with perspectives from Kevin Weeks, Professor, UNC to help structure your research into targeting RNA I hope you can join this rapidly emerging community in Boston this December in order to overcome the target identification and validation, selective binding and chemistry challenges facing those trying to translate novel small molecules that successfully target therapeutically relevant RNA, and accelerate them into the clinic.